G. Steven Burrill is CEO of Burrill & Company, a San Francisco-based life science merchant bank with over $500 million under management. In 2002, Burrill was recognized as a biotech investment visionary by Scientific American. He currently serves as chairman of the boards of Icoria, Pharmasset, and Pyxis Genomics and is a member of the boards of Catalyst Biosciences, DepoMed, Galapagos Genomics, Targacept, and Third Wave Technologies. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.